EIM
HZNP

Essex Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Essex Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-75,000
Closed -$1.24M – 366
2016
Q2 		$1.24M Hold
75,000
– – 0.21% 114
2016
Q1 		$1.24M Hold
75,000
– – 0.21% 106
2015
Q4 		$1.63M Buy
+75,000
New +$1.46M 0.25% 95

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Essex Investment Management's HZNP Position: Q3 2016 in Review

Essex Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2016, closing a stake of 75,000 shares — an estimated $1.24M sold.

Essex Investment Management first reported a position in HZNP in Q4 2015 and held it in 3 quarters. The position peaked at $1.63M in Q4 2015. 232 funds tracked by Wall St. Rank hold HZNP as of Q3 2016.

  • Essex Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2016 after selling out during the quarter.
  • Essex Investment Management sold 75,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2016, an estimated $1.24M.
  • Essex Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 3 quarters.
  • Essex Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.63M in Q4 2015.
  • 232 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2016.

Based on Essex Investment Management's 13F filing for Q3 2016, filed 1 Nov 2016.